|
You may have heard a thing or two about the past life of Dr. Sy Schlager. Perhaps you’ve heard about his medical ventures and the fact that he led major efforts to get the FDA on board with the creation of orphan drugs or the maybe the fact that he directed the developmental efforts of antiviral products, in order to make a discovery within the HIV/AIDS field. These two things about Sy Schlager are in fact true, as he is an innovative and engineering force within the medical field. It’s important to review the work of Schlager when studying pioneering medical professionals. In fact, over the last 10 years, Dr. Schlager has focused his professional identity on medical education and communication. He works to apply his diverse background and academic achievements to the creation and generation of healthcare communications programs and materials. As the former venture head of the AIDS/Antiviral Venture at Abbott Laboratories, Sy Schlager directed all the creation efforts of antiviral products, including the development of HIV protease inhibitor and clarithromycin for Mycobacterial infections in AIDS patients. To further invent cutting edge technologies, Sy Schlager also served as the company’s key marketing personnel. He played the role of primary public relations liaison for print and televised news media groups and AIDS activists. It’s important to realize that Schlager is also an AIDS activist himself, constantly searching for a cure and some way to soothe the immense pain and suffering that those diagnosed go through. Medical professionals, such as Schlager, have received recognition within the AIDS community. In addition to the above immense efforts, Dr. Schlager also directed Phase I-III clinical trials in various therapeutic areas, including anti-infectives, anti-hypertensives, CNS and anti-inflammatory agents. Any credit that Schlager receives in the medical community should have something to do with his groundbreaking efforts as the venture head at Abbott Laboratories. He excelled within this position and he only pushed his medical expertise that much further. As mentioned earlier, Sy Schlager also coordinated and directed the preclinical development of compounds that held prospective opportunities for the creation of orphan drugs. As the senior director for clinical research and product development at Academic Pharmaceuticals, Inc., Schlager represented the company before the FDA, in order to allow Orphan Drug Act exceptions. This was done in order to increase the promise of tomorrow for anti-arrhythmic drug candidates. He also led licensing and co-marketing agreements with other pharmaceutical companies in hopes to further press on with the complex advancement of orphan drugs. As one can see, Dr. Sy Schlager worked in various differing platforms in order to help those that often go unnoticed. As many doctors would diagnose these patients as “incurable,” Schlager is working on ways to improve their quality of life and possibly the creation of a cure. To learn more visit http://syschlagerblog.com & http://syschlagerblog.net.
Related Articles -
Sy, Schlager,
|
